JPRN-UMIN000029422已完成未知
The study of combination therapy with radium-223 and enzalutamide in Osaka City University - CORE-OCU study
Osaka City University Graduate School of Medicine0 个研究点目标入组 10 人开始时间: 2017年10月4日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •1) Prior chemotherapy or planned treatment with chemotherapy 2) Prior PSA primary resistance to enzalutamide within previous 3 months 3) Systemic radiotherapy with strontium-89, samarium-153, rhenium-186 or rhenium-188 for the treatment of bone metastases within previous 24 weeks 4) Prior treatment with radium-223 5) Had history of gastrointestinal bleeding or ulcer within 3 months prior to study entry 6) History of visceral metastasis, or presence of visceral metastasis detected by screening imaging examinations 7) History of or known brain metastasis 8) Malignant lymphadenopathy exceeding 1.5 cm in short-axis diameter 9) Imminent or established spinal cord compression based on clinical findings and/or MRI (Magnetic Resonance Imaging) 10) Any serious complication for using rad-223 11) Any other serious illness or medical, psychological or social condition may interfere with the subject's participation in the study or evaluation of the study results 12) Those who judged to be inappropriate by the principal investigator or co-investigator
研究者
相似试验
进行中（未招募）
1 期
Radium-223 & Enzalutamide metastatic prostate cancer studyEUCTR2013-004850-97-IECancer Trials Ireland44
已完成
2 期
Radium-223 in Combination With EnzalutamideProstate CancerNCT02225704Cancer Trials Ireland45
进行中（未招募）
1 期
A phase II clinical trial of radium-223 activity in patients with metastatic castration-resistant prostate cancer (mCRPC) with asymptomatic progression while on abiraterone acetate or enzalutamide besides AR-V7 mutational statusPatients with mCRPC with asymptomatic progression while on abiraterone acetate or enzalutamideMedDRA version: 19.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001888-36-ESMedica Scientia Innovation Research (MedSIR ARO)52
Unknown
2 期
The Combination Therapy With Ra-223 and EnzalutamideCastration-resistant Prostate CancerBone MetastasesNCT03305224Taro Iguchi, MD, PHD10
招募中
2 期
A phase II study of combination of radiotherapy and Atezolizumab/nab-paclitaxel for inoperable or recurrent PD-L1 positive triple negative breast cancerinoperable or recurrent PD-L1 positive triple negative breast cancerJPRN-jRCTs021210010Suzuki Yoshiyuki20